NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Earnings Season Heats Up as Over 120 Companies Declare Q4 2026 Results

Amid the ongoing earnings season, more than 120 companies are scheduled to release their financial results for the quarter ended on 31, 2026, on Tuesday, 19 May. This includes major companies such as Bharat Electronics, Bharat Petroleum Corporation, Mankind Pharma, Zydus Lifesciences, and Zee Entertainment Enterprises, who are among the first to declare their Q4 2026 results today.

The key Q4 earnings announcements scheduled today are expected to influence sectoral momentum, with major companies to watch including BPCL, Bharat Electronics (BEL), and Zydus Lifesciences. Benchmark indices Sensex and Nifty 50 closed marginally higher on Monday, May 18, recovering sharply from intraday lows amid buying interest in select heavyweight stocks. The 30-share Sensex gained 77 points, or 0.10%, to end at 75,315.04, while the Nifty 50 edged up 6 points, or 0.03%, to settle at 23,649.95.

Bharat Electronics Q4 Results Preview Brokerage firm Motilal Oswal expects BEL's revenue growth of 14% YoY, led by the healthy execution of the opening order book of ₹730 billion. It further anticipates margins to contract 320bp YoY to 27.4% on a high base but remain at strong levels for FY26. Bharat Electronics released provisional figures reporting orders worth ₹300 billion, including export orders valued at $346 million. Revenue, excluding other operating income, stood at ₹268 billion, marking a 16% year-on-year (YoY) increase, while export revenue rose 34% YoY to $142 million.

Read also: Market Analysis: Key Stocks to Watch - Narayana Hrudayalaya, ABB India, Federal Bank, Premier Energies, Ather Energy and More

Mankind Pharma Q4 Results Preview Brokerage firm Kotak Institutional Equities expects 10% YoY sales growth rate for Mankind's organic domestic business in 4QFY26, compared to the 9% YoY growth rate (adjusted for Mahananda divestment) in 3QFY26. The brokerage firm is also factoring in 5% YoY growth in Mankind's organic international business and accordingly expect Mankind's overall organic business to grow 9% YoY in 4QFY26.

CompanyQ4FY26 Sales Growth Rate (YoY)
Mankind's Organic Domestic Business10%
Mankind's Organic International Business5%
Mankind's Overall Organic Business9%
Mankind's Overall Sales9% (YoY), -6% (QoQ)
Mankind's Gross Margin70.5% (-110 bps YoY)
Mankind's Consolidated Reported EBITDA₹7.6 billion (11% YoY, -18% QoQ)

Investor Takeaway

Monitor key Q4 earnings announcements for sectoral momentum.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.